Dr. Daneng Li, M.D.
Medical Oncology (Medical Oncology Physician)
1500 Duarte Rd
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 222
Licensed in California since 2015, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Js Weill Medical College, Cornell University
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A137025 (first issued 2015; current) -
Internal Medicine Physician
NY license 264456
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence St. Jude Medical Center Fullerton, CA
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 222
- Services billed
- 1,427
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 485 | 159 |
| Established patient office or other outpatient visit, 40-54 minutes | 426 | 148 |
| New patient office or other outpatient visit, 60-74 minutes | 72 | 72 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lenvima (lenvatinib mesylate) | 12 |
| Sandostatin Lar Depot (octreotide acetate,mi-spheres) | 12 |
| Ondansetron Hcl Other prescribers in Duarte, CA | 11 |
| Prochlorperazine Maleate Other prescribers in Duarte, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 32 payments worth $37,172 in total to this clinician.
| Coherus Oncology, Inc. | $10,016 |
|---|---|
| Merck Sharp & Dohme LLC | $8,456 |
| Tersera Therapeutics LLC | $3,936 |
| Exelixis Inc. | $3,265 |
| Partner Therapeutics, Inc. | $3,066 |
| Boehringer Ingelheim International GmbH | $2,220 |
| Genentech, Inc. | $1,768 |
| AbbVie Inc. | $1,450 |
| Consulting Fee | $24,100 |
|---|---|
| Honoraria | $7,515 |
| Travel and Lodging | $2,969 |
| Compensation for services other than consulting (speaking, faculty) | $1,711 |
| Food and Beverage | $876 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee | $7,040 |
| Coherus Oncology, Inc. Sep 28, 2025 | Honoraria LOQTORZI · Oncology | $4,875 |
| Coherus Oncology, Inc. Sep 28, 2025 | Consulting Fee LOQTORZI · Oncology | $4,875 |
| Tersera Therapeutics LLC Oct 22, 2025 | Consulting Fee Xermelo · Oncology | $3,430 |
| Partner Therapeutics, Inc. Jan 9, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| Exelixis Inc. Jun 23, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,640 |
| Boehringer Ingelheim International GmbH Sep 29, 2025 | Consulting Fee | $2,220 |
| AbbVie Inc. Mar 26, 2025 | Consulting Fee | $1,450 |
| Novartis Pharmaceuticals Corporation Dec 11, 2025 | Consulting Fee LUTATHERA · Oncology | $1,400 |
| Ipsen Pharma Sas Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $910 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 11, 2025 | Consulting Fee LUTATHERA · Oncology | $1,400 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee | $7,040 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging travel to Washington, DC | $150 |
| Merck Sharp & Dohme LLC Nov 6, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $234 |
| Merck Sharp & Dohme LLC Nov 6, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $123 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $546 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $229 |
| Tersera Therapeutics LLC Oct 22, 2025 | Consulting Fee Xermelo · Oncology | $3,430 |
| Tersera Therapeutics LLC Oct 22, 2025 | Travel and Lodging Xermelo · Oncology · travel to Austin, TX · in-kind | $395 |
| Boehringer Ingelheim International GmbH Sep 29, 2025 | Consulting Fee | $2,220 |
| Coherus Oncology, Inc. Sep 28, 2025 | Honoraria LOQTORZI · Oncology | $4,875 |
| Coherus Oncology, Inc. Sep 28, 2025 | Consulting Fee LOQTORZI · Oncology | $4,875 |
| Ipsen Pharma Sas Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $910 |
| Exelixis Inc. Jun 23, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,640 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $417 |
| AbbVie Inc. Mar 26, 2025 | Consulting Fee | $1,450 |
| AstraZeneca Pharmaceuticals LP Mar 4, 2025 | Consulting Fee | $685 |
| Genentech, Inc. Feb 11, 2025 | Travel and Lodging Tecentriq · BioOncology · travel to Toronto, ONTARIO, Canada | $810 |
| Genentech, Inc. Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) Tecentriq · BioOncology | $801 |
| Partner Therapeutics, Inc. Jan 9, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| Partner Therapeutics, Inc. Jan 9, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to Manhattan Beach, CA | $65.86 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 6 companies. The companies reported $3,012,335 in research payments for these studies, mostly to the institutions running them.
- A Phase Ib Study of Durvalumab and Tremelimumab Following Radioembolization in Patients with Unresectable Locally Advanced Hepatocellular Carcinoma
AstraZeneca Pharmaceuticals LP - A Phase 1b,2 Open-Label, Dose Escalation of ADG106 in Combination with Pembrolizumab Anti PD-1 Antibody and Expansion of ADG106 with or without Pembrolizumab in Patients with Advanced or Metastatic Solid and,or Hemato…
Merck Sharp & Dohme LLC - SRF388-201
Coherus Oncology, Inc. - A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT06109272 - PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC
Genentech, Inc. - CHS38802
Coherus Oncology, Inc. - Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie Inc. - M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatoce…
AbbVie Inc. - A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.